| Literature DB >> 22363838 |
Abstract
Alkylresorcinols (ARs) were first proposed as potential biomarkers of wholegrain wheat and rye intake a decade ago. Since then there has been a considerable body of research which suggests that ARs do meet most criteria of a biomarker of these foods. Results from human studies on plasma AR and their plasma and urinary metabolites strongly indicate that these compounds are responsive to whole grain wheat and rye intake and are correlated with various measures of AR consumption. This review briefly summarises work on the bioactivities of AR and focuses on aspects related to their use as biomarkers of whole grain wheat and rye intake. Evidence suggests that they thus far broadly fulfil the criteria to act as biomarkers of these cereals. However, there are still gaps in the knowledge on factors relating to the wide interindividual variation, and application to different epidemiological cohorts. Overall, ARs are highly promising biomarkers of whole grain wheat and rye intake and add to our increasing understanding of whole grains and health.Entities:
Year: 2012 PMID: 22363838 PMCID: PMC3270436 DOI: 10.1155/2012/462967
Source DB: PubMed Journal: J Nutr Metab ISSN: 2090-0724
Figure 1Basic structure of alkylresorcinols (a), and the two main plasma and urinary metabolites, 3,5-dihydroxybenzoic acid (b), and 3,5-dihydroxyphenylpropianoic acid (c). For the most abundant alkylresorcinols in cereals, R = C17H35–C25H51.
Figure 2GC-MS chromatograms of the main AR containing cereals: wheat, rye, and barley. The ratio of the different odd-numbered saturated homologues varies from grain to grain but is generally conserved from variety to variety. The ratio C17 : 0/C21 : 0 can be used to determine if a cereal sample is wheat (~0.1) or rye (~1.0) and is reflected partially in plasma.
Key steps for validating a biomarker, and if alkylresorcinols meet these criteria as biomarkers of alkylresorcinol containing foods (adapted from [75, 82]).
|
| ||
|
| ||
| Quantitative analytical methods for grains and food | GC | [ |
| HPLC | [ | |
| Colorimetry | [ | |
|
| ||
| Not present in other foods | In food plants, only found in wheat, rye and barley, and genetically related crops, and in low amounts in mango flesh. Very low amounts in beer and animal fat. | [ |
|
| ||
| Not affected by food processing | AR stable during baking and pasta production | [ |
| Limited effect of fermentation and germination in rye | [ | |
|
| ||
| Variation in raw material | Wheat (350–900 | [ |
| Rye (500–1300 | [ | |
| Barley (30–100 | [ | |
|
| ||
|
| ||
|
| ||
| Quantitative analytical methods for biological samples | GC-MS (plasma, erythrocytes, adipose tissue, urinary metabolites) | [ |
| GC-MS/MS (plasma, erythrocytes) | [ | |
| LC-MS/MS (plasma) | [ | |
| HPLC-CAED (metabolites) | [ | |
|
| ||
| Intake | Average intake in the UK and Sweden estimated to be 12 and 23 mg/d, respectively | [ |
|
| ||
| Absorption | Pigs: 60–79% depending on dose | [ |
| Humans: 58% ileal absorption | [ | |
|
| ||
| Distribution | Rats: negligible accumulation 100 h after a single dose | [ |
| Adipose: AR-measured in rat and human adipose | [ | |
|
| ||
| Metabolism | Main AR metabolites in humans: DHBA and DHPPA | [ |
| DHBA and DHPPA also measured in human plasma | [ | |
| DHPPA extensively glucuronidated in human urine | [ | |
|
| ||
| Elimination | 61% and 31% of a single dose eliminated in faeces and urine in rats | [ |
| Urinary recovery 45–89% depending on dose | [ | |
|
| ||
|
| ||
|
| ||
| Dose response | Increased dose of AR leads to decreased absorption in pigs | [ |
| Urinary recovery % lower with increased AR dose | [ | |
|
| ||
| Pharmacokinetics | Pigs: | [ |
| Humans: | [ | |
| Plasma metabolites: | [ | |
|
| ||
|
| ||
|
| ||
| Determinants of plasma alkylresorcinol concentration | Gender: males have generally higher concentrations | [ |
| Triglycerides and lipoproteins | [ | |
| Nonesterified fatty acids | [ | |
|
| ||
| Variation in different populations | Healthy subjects, fasting plasma | |
| Mixed results for females with hormone-related cancers | [ | |
|
| ||
| Reproducibility and validity | Intervention studies: good-to-moderate ICC | [ |
| Free-living studies: low ICC | [ | |
|
| ||
|
| ||
|
| ||
| Surrogate endpoint for WG intake | Endometrial cancer case-control study: no difference in nonfasting plasma AR | [ |
|
| ||
| Validation of dietary assessment tools | WG FFQ: correlation with FFQ: 0.53 | [ |
|
| ||
| Biomarker of compliance to an intervention | WG interventions | [ |
Figure 3Relationship between mean AR intake and the mean of plasma AR across published studies (a). Where direct AR intake data was not provided, it was estimated from literature values if possible. Values are arithmetic means, and error bars are the standard deviation. Figure (b) uses data from studies where there has been an arm/group with an AR intake equivalent to 0–48 g of WG wheat (0–27 mg AR/d) to give an idea of the range at “normal” intakes, as well as the likely intercept for no WG intake.
Figure 4An example of interindividual variation of plasma alkylresorcinols under controlled conditions. The wholegrain intervention delivered approximately 62 mg alkylresorcinols/d. Each time point is one week apart. Data are from [51].
Figure 5Relationship between mean AR intake and the mean of urinary AR from three published studies. Where direct AR intake data was not provided, it was estimated from literature values if possible. Values are arithmetic means, and error bars are the standard deviation.
Correlations of plasma alkylresorcinol concentration with different measurements of wholegrain intake from previously published studies.
|
| Gender | Country | Type of study | Dietary assessment method | Dietary exposure parameter | Correlation |
| C17 : 0/C21 : 0 | Reference |
|---|---|---|---|---|---|---|---|---|---|
| 39 | Fa | Finland | Intervention | 4DFRb | Rye bread intake | 0.34 | 0.037 | 0.84 | [ |
| 39 | F | Finland | Intervention | 4DFR | Insoluble fibre | 0.39 | 0.013 | 0.84 | [ |
| 28 | F+M | Sweden | Intervention | 3DFRc | AR | 0.58 | <0.001 | 0.30 | [ |
| 56 | F | Finland | Free-living | 5DFRd | Cereal fibre | 0.38 | 0.004 | 0.62 | [ |
| 29 | F+M | Switzerland | Free-living | 3DWFRe | WG intake | 0.57 | <0.001 | 0.17 | [ |
| 29 | F+M | Switzerland | Free-living | WG FFQf | WG intake | 0.55 | <0.001 | 0.17 | [ |
| 360 | F | Denmark | Prospective | FFQg | Rye bread intake | 0.25 | <0.001 | 0.40 | [ |
| 266 | F+M | UK | Intervention | FFQ | WG intake | 0.35i | <0.001 | 0.07 | [ |
| 266 | F+M | UK | Intervention | FFQ | WWh intake | 0.43i | <0.001 | 0.07 | [ |
| 266 | F+M | UK | Intervention | FFQ | AR intake | 0.39i | <0.001 | 0.07 | [ |
aF: female, M: male
b4DFR: 4-day food record
c3DFR: 3-day food record
d5DFR: 5-day food record
e3DWFD: 3-day weighed food diary
fWG-FFQ: Wholegrain food frequency questionnaire
gGeneral diet food frequency questionnaire
hWW: Wholegrain wheat
iAfter 16-week intervention.
Correlations of plasma and urinary alkylresorcinol metabolites (DHBA and DHPPA) with different measurements of wholegrain intake from previously published studies.
| N | Gender | Country | Type of study | Dietary assessment method | Diet exposure parameter | AR metabolite | Plasma/urine | Correlation |
| Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| 56 | Fa | Finland | Free-living | 5DFRb | Cereal fibre | DHBAc | 24 h urine | 0.37 | 0.005 | [ |
| 56 | F | Finland | Free-living | 5DFR | Cereal fibre | DHPPAd | 24 h urine | 0.41 | 0.002 | [ |
| 56 | F | Finland | Free-living | 5DFR | Cereal fibre | DHBA | Plasma | 0.41 | <0.01 | [ |
| 56 | F | Finland | Free-living | 5DFR | Cereal fibre | DHPPA | Plasma | 0.46 | <0.01 | [ |
| 56 | F | Finland | Free-living | 5DFR | Cereal fibre | Total AR metabolites | Plasma | 0.42 | <0.01 | [ |
| 60 | F | Finland | Free-living | 5DFR | Rye | DHBA | Plasma | 0.32 | <0.05 | [ |
| 60 | F | Finland | Free-living | 5DFR | Rye | DHPPA | Plasma | 0.39 | <0.01 | [ |
| 60 | F | Finland | Free-living | 5DFR | Rye | Total AR metabolites | Plasma | 0.33 | <0.05 | [ |
| 60 | F | Finland | Free-living | 5DFR | Rye | DHBA | 24 h urine | 0.52 | <0.001 | [ |
| 60 | F | Finland | Free-living | 5DFR | Rye | DHPPA | 24 h urine | 0.44 | <0.001 | [ |
| 60 | F | Finland | Free-living | 5DFR | Rye | Total AR metabolites | 24 h urine | 0.48 | <0.001 | [ |
aF: female
b5DFR: 5-day food record
cDHBA: 3,5-dihydroxybenzoic acid
dDHPPA: 3,5-dihydroxyphenylpropionoic acid.
Plasma AR concentrations when subjects have consumed low or essentially AR-free diets.
|
| Gender | Country | AR intake (mg/d) | Intervention type | Duration of intervention period (weeks) | Median | Mean | SD | Range | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| 39 | Fa | FI | 5.34b | Replace all bread with intervention breads | 8 | 36.6 | 26.2 | 10.9–55.8c | [ | |
| 15 | F+M | FI | 3b | Replace all bread with intervention breads | 1 | 25–30 | 12–41 | 5.5–171 | [ | |
| 28 | F+M | SE | 6.8 | All cereal foods provided | 6 | 59 | 57 | 9–220 | [ | |
| 17 | M | SE | 8.2 | Replace all cereal foods | 6 | 33 | 72 | 101 | 17–410 | [ |
| 17 | F+M | CH | 5 | Fully controlled diet | 2 | 40 | 44 | 17 | 27–89 | [ |
| 34 | F | DK | 3.1d | Replace part of cereals in diet | 12 | 61 | 78 | 43.7 | 16–246 | [ |
| 266 | F+M | UK | 17 | WG consumption < 30 g/d | 0 | 69.5 | 84.3 | 136 | 10–875 | [ |
| 16 | F+M | SE | WG-free diet | Avoid all WG foods | 1 | 60–68 | 33–37 | 23–178 | [ | |
| 17 | F+M | CH | WG-free diet | Avoid all WG foods | 1 | 19–32 | 25–38 | 13–21 | 7–82 | [ |
a F: female, M: male
bEstimated intake from refined wheat bread intake
cExcludes outliers
dAmount provided by intervention, not total diet.